{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:49:04Z","timestamp":1792788544230,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Beijing Municipality","award":["7262011"],"award-info":[{"award-number":["7262011"]}]},{"name":"Beijing Research Ward Excellence Program","award":["BRWEP2024W032040204"],"award-info":[{"award-number":["BRWEP2024W032040204"]}]},{"name":"National Natural Science Foundation of China","award":["82573705"],"award-info":[{"award-number":["82573705"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Science and Technology Major Project for Innovative Drug Development","award":["No. 2026ZD1804600, No. 2026ZD1804601"],"award-info":[{"award-number":["No. 2026ZD1804600, No. 2026ZD1804601"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"DOI":"10.1186\/s40478-026-02360-5","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:16:04Z","timestamp":1782911764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MET-associated immune prognostic signature predicts survival and guides personalized therapy in glioma"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7613-6188","authenticated-orcid":false,"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-6557","authenticated-orcid":false,"given":"Chengjun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaodong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changlin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4922-4470","authenticated-orcid":false,"given":"Zhaoshi","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2360_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1146\/annurev-pathmechdis-042524-025950","volume":"21","author":"J Li","year":"2026","unstructured":"Li J, Ross JL, Hambardzumyan D, Brat DJ (2026) Immunopathology of glioblastoma Annu Rev Pathol 21:135\u2013162. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-042524-025950.","journal-title":"Annu Rev Pathol"},{"key":"2360_CR2","doi-asserted-by":"publisher","first-page":"218185","DOI":"10.1016\/j.canlet.2025.218185","volume":"640","author":"T Jiang","year":"2025","unstructured":"Jiang T, Nam DH, Ram Z, Poo WS, Wang J, Boldbaatar D, Mao Y, Ma W, Mao Q, You Y et al (2025) Updated clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett 640:218185. https:\/\/doi.org\/10.1016\/j.canlet.2025.218185","journal-title":"Cancer Lett"},{"key":"2360_CR3","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/s41467-021-21117-3","volume":"12","author":"E Jung","year":"2021","unstructured":"Jung E, Osswald M, Ratliff M, Dogan H, Xie R, Weil S, Hoffmann DC, Kurz FT, Kessler T, Heiland S et al (2021) Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma. Nat Commun 12:1014. https:\/\/doi.org\/10.1038\/s41467-021-21117-3","journal-title":"Nat Commun"},{"key":"2360_CR4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ccell.2021.05.002","volume":"39","author":"T Hara","year":"2021","unstructured":"Hara T, Chanoch-Myers R, Mathewson ND, Myskiw C, Atta L, Bussema L, Eichhorn SW, Greenwald AC, Kinker GS, Rodman C et al (2021) Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell 39:779\u201392e11. https:\/\/doi.org\/10.1016\/j.ccell.2021.05.002","journal-title":"Cancer Cell"},{"key":"2360_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s40364-025-00863-2","volume":"13","author":"J Cvitkovi\u0107","year":"2025","unstructured":"Cvitkovi\u0107 J, Tan WL, Jiang T, Zhao Z (2025) Glioma tumor microenvironment and immunotherapy: past, present, and future. Biomark Res 13:150. https:\/\/doi.org\/10.1186\/s40364-025-00863-2","journal-title":"Biomark Res"},{"key":"2360_CR6","doi-asserted-by":"publisher","first-page":"e45969","DOI":"10.1371\/journal.pone.0045969","volume":"7","author":"GY Stein","year":"2012","unstructured":"Stein GY, Yosef N, Reichman H, Horev J, Laser-Azogui A, Berens A, Resau J, Ruppin E, Sharan R, Tsarfaty I (2012) Met kinetic signature derived from the response to HGF\/SF in a cellular model predicts breast cancer patient survival. PLoS ONE 7:e45969. https:\/\/doi.org\/10.1371\/journal.pone.0045969","journal-title":"PLoS ONE"},{"key":"2360_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12964-025-02033-1","volume":"23","author":"Y Xia","year":"2025","unstructured":"Xia Y, Huang C, Zhong M, Zhong H, Ruan R, Xiong J, Yao Y, Zhou J, Deng J (2025) Targeting HGF\/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion. Cell Commun Signal 23:46. https:\/\/doi.org\/10.1186\/s12964-025-02033-1","journal-title":"Cell Commun Signal"},{"key":"2360_CR8","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.cell.2018.09.038","volume":"175","author":"H Hu","year":"2018","unstructured":"Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, Wang K, Wang Z, Nam Y, Jiang B et al (2018) Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell 175:1665\u20131678. https:\/\/doi.org\/10.1016\/j.cell.2018.09.038","journal-title":"Cell"},{"key":"2360_CR9","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.jtho.2020.11.014","volume":"16","author":"X Yang","year":"2021","unstructured":"Yang X, Li Y, Duan Q, Zhang Q, He M (2021) Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment. J Thorac Oncol 16:e17\u2013e9. https:\/\/doi.org\/10.1016\/j.jtho.2020.11.014","journal-title":"J Thorac Oncol"},{"key":"2360_CR10","doi-asserted-by":"publisher","first-page":"102221","DOI":"10.1016\/j.ctrv.2021.102221","volume":"98","author":"AB El-Khoueiry","year":"2021","unstructured":"El-Khoueiry AB, Hanna DL, Llovet J, Kelley RK (2021) Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treat Rev 98:102221. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102221","journal-title":"Cancer Treat Rev"},{"key":"2360_CR11","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jtho.2021.02.010","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge DR, Otterson GA, Clark JW, Ignatius Ou SH, Weiss J, Ades S, Shapiro GI, Socinski MA, Murphy DA, Conte U et al (2021) Crizotinib in Patients With MET-Amplified NSCLC. J Thorac Oncol 16:1017\u20131029. https:\/\/doi.org\/10.1016\/j.jtho.2021.02.010","journal-title":"J Thorac Oncol"},{"key":"2360_CR12","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1038\/s41388-020-1193-8","volume":"39","author":"JP Koch","year":"2020","unstructured":"Koch JP, Aebersold DM, Zimmer Y, Medov\u00e1 M (2020) MET targeting: time for a rematch. Oncogene 39:2845\u20132862. https:\/\/doi.org\/10.1038\/s41388-020-1193-8","journal-title":"Oncogene"},{"key":"2360_CR13","doi-asserted-by":"publisher","first-page":"e13198","DOI":"10.1111\/bpa.13198","volume":"34","author":"L Liu","year":"2024","unstructured":"Liu L, Zhang KN, Zhao Z, Li G, Chai RC, Li Z, Liu X, Chen J, Jiang T (2024) MET fusions and splicing variants is a strong adverse prognostic factor in astrocytoma, isocitrate dehydrogenase mutant. Brain Pathol 34:e13198. https:\/\/doi.org\/10.1111\/bpa.13198","journal-title":"Brain Pathol"},{"key":"2360_CR14","doi-asserted-by":"publisher","first-page":"e70085","DOI":"10.1002\/2056-4538.70085","volume":"12","author":"Z Fang","year":"2026","unstructured":"Fang Z, Zheng C, Wang P, Liu X, Liu L, Li G, Dong J, Chen Q, Zhang D, Feng Y et al (2026) MET fusions and splicing variants in glioma: a landscape integrating clinical, pathological, and survival features. J Pathol Clin Res 12:e70085. https:\/\/doi.org\/10.1002\/2056-4538.70085","journal-title":"J Pathol Clin Res"},{"key":"2360_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s44178-022-00014-9","volume":"1","author":"K Zhang","year":"2022","unstructured":"Zhang K, Zhao Z, Chen J, Bao Z, Chai R-C, Sun Z, Wu L, Wang Z, Liu H, Mu Q et al (2022) MET fusions and splicing variants convergently define a subgroup of glioma sensitive to MET inhibitors. Holist Integr Oncol 1:18","journal-title":"Holist Integr Oncol"},{"key":"2360_CR16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","volume":"17","author":"R Guo","year":"2020","unstructured":"Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A (2020) MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol 17:569\u2013587. https:\/\/doi.org\/10.1038\/s41571-020-0377-z","journal-title":"Nat Rev Clin Oncol"},{"key":"2360_CR17","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.3390\/ijms25116109","volume":"25","author":"AM Lombardi","year":"2024","unstructured":"Lombardi AM, Sangiolo D, Vigna E (2024) MET oncogene targeting for cancer immunotherapy. Int J Mol Sci 25:6109. https:\/\/doi.org\/10.3390\/ijms25116109","journal-title":"Int J Mol Sci"},{"key":"2360_CR18","doi-asserted-by":"publisher","first-page":"1498391","DOI":"10.3389\/fimmu.2024.1498391","volume":"15","author":"P Jabbarzadeh Kaboli","year":"2024","unstructured":"Jabbarzadeh Kaboli P, Roozitalab G, Farghadani R, Eskandarian Z, Zerrouqi A (2024) c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity. Front Immunol 15:1498391. https:\/\/doi.org\/10.3389\/fimmu.2024.1498391","journal-title":"Front Immunol"},{"key":"2360_CR19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s13046-021-02055-w","volume":"40","author":"E Li","year":"2021","unstructured":"Li E, Huang X, Zhang G, Liang T (2021) Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. J Exp Clin Cancer Res 40:279. https:\/\/doi.org\/10.1186\/s13046-021-02055-w","journal-title":"J Exp Clin Cancer Res"},{"key":"2360_CR20","doi-asserted-by":"publisher","first-page":"7044","DOI":"10.1002\/cam4.2542","volume":"8","author":"G Tong","year":"2019","unstructured":"Tong G, Cheng B, Li J, Wu X, Nong Q, He L, Li X, Li L, Wang S (2019) MACC1 regulates PDL1 expression and tumor immunity through the c-Met\/AKT\/mTOR pathway in gastric cancer cells. Cancer Med 8:7044\u20137054. https:\/\/doi.org\/10.1002\/cam4.2542","journal-title":"Cancer Med"},{"key":"2360_CR21","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1158\/1078-0432.Ccr-18-0267","volume":"24","author":"M Saigi","year":"2018","unstructured":"Saigi M, Alburquerque-Bejar JJ, Mc Leer-Florin A, Pereira C, Pros E, Romero OA, Baixeras N, Esteve-Codina A, Nadal E, Brambilla E et al (2018) MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer. Clin Cancer Res 24:4579\u20134587. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0267","journal-title":"Clin Cancer Res"},{"key":"2360_CR22","first-page":"564","volume":"10","author":"X Sun","year":"2020","unstructured":"Sun X, Li CW, Wang WJ, Chen MK, Li H, Lai YJ, Hsu JL, Koller PB, Chan LC, Lee PC et al (2020) Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma. Am J Cancer Res 10:564\u2013571","journal-title":"Am J Cancer Res"},{"key":"2360_CR23","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1053\/j.gastro.2019.01.252","volume":"156","author":"H Li","year":"2019","unstructured":"Li H, Li CW, Li X, Ding Q, Guo L, Liu S, Liu C, Lai CC, Hsu JM, Dong Q et al (2019) MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1. Gastroenterology 156:1849\u201361e13. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.252","journal-title":"Gastroenterology"},{"key":"2360_CR24","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1158\/0008-5472.Can-22-0770","volume":"82","author":"R Yoshida","year":"2022","unstructured":"Yoshida R, Saigi M, Tani T, Springer BF, Shibata H, Kitajima S, Mahadevan NR, Campisi M, Kim W, Kobayashi Y et al (2022) MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer. Cancer Res 82:4079\u20134092. https:\/\/doi.org\/10.1158\/0008-5472.Can-22-0770","journal-title":"Cancer Res"},{"key":"2360_CR25","doi-asserted-by":"publisher","first-page":"e002451","DOI":"10.1136\/jitc-2021-002451","volume":"9","author":"QW Wang","year":"2021","unstructured":"Wang QW, Sun LH, Zhang Y, Wang Z, Zhao Z, Wang ZL, Wang KY, Li GZ, Xu JB, Ren CY et al (2021) MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas. J Immunother Cancer 9:e002451. https:\/\/doi.org\/10.1136\/jitc-2021-002451","journal-title":"J Immunother Cancer"},{"key":"2360_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/cns.13627","volume":"27","author":"R Huang","year":"2021","unstructured":"Huang R, Liu Y, Wang K, Wang Z, Zhang C, Zhang W, Zhao Z, Li G, Huang L, Chang Y et al (2021) High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation. CNS Neurosci Ther 27:617\u2013628. https:\/\/doi.org\/10.1111\/cns.13627","journal-title":"CNS Neurosci Ther"},{"key":"2360_CR27","doi-asserted-by":"publisher","first-page":"107820","DOI":"10.1016\/j.lungcan.2024.107820","volume":"192","author":"E Felip","year":"2024","unstructured":"Felip E, Metro G, Tan DSW, Wolf J, Mark M, Boyer M, Hughes BGM, Bearz A, Moro-Sibilot D, Le X et al (2024) Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer. Lung Cancer 192:107820. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107820","journal-title":"Lung Cancer"},{"key":"2360_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.01.012","author":"B McGregor","year":"2023","unstructured":"McGregor B, Geynisman DM, Burotto M, Su\u00e1rez C, Bourlon MT, Barata PC, Gulati S, Huo S, Ejzykowicz F, Blum SI et al (2023) A matching-adjusted indirect comparison of nivolumab plus cabozantinib versus pembrolizumab plus axitinib in patients with advanced renal cell carcinoma. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2023.01.012. S2588-9311:00031\u2009\u2013\u20097","journal-title":"Eur Urol Oncol"},{"key":"2360_CR29","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/s41419-021-04427-8","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Ma W, Fan W, Ren C, Xu J, Zeng F, Bao Z, Jiang T, Zhao Z (2021) Comprehensive transcriptomic characterization reveals core genes and module associated with immunological changes via 1619 samples of brain glioma. Cell Death Dis 12:1140. https:\/\/doi.org\/10.1038\/s41419-021-04427-8","journal-title":"Cell Death Dis"},{"key":"2360_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.bioactmat.2025.07.015","volume":"53","author":"C Zheng","year":"2025","unstructured":"Zheng C, Wang P, Zhang D, Fang Z, Feng Y, Chen J, Chen J, Fu Y, Yang B, Yu S et al (2025) A novel organoid model retaining the glioma microenvironment for personalized drug screening and therapeutic evaluation. Bioact Mater 53:205\u2013217. https:\/\/doi.org\/10.1016\/j.bioactmat.2025.07.015","journal-title":"Bioact Mater"},{"key":"2360_CR31","doi-asserted-by":"publisher","first-page":"djw262","DOI":"10.1093\/jnci\/djw262","volume":"109","author":"AB Cortot","year":"2017","unstructured":"Cortot AB, Kherrouche Z, Descarpentries C, Wislez M, Baldacci S, Furlan A, Tulasne D (2017) Exon 14 deleted MET receptor as a new biomarker and target in cancers. J Natl Cancer Inst 109:djw262. https:\/\/doi.org\/10.1093\/jnci\/djw262","journal-title":"J Natl Cancer Inst"},{"key":"2360_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21037\/atm.2016.12.33","volume":"5","author":"S Pilotto","year":"2017","unstructured":"Pilotto S, Gkountakos A, Carbognin L, Scarpa A, Tortora G, Bria E (2017) MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy. Ann Transl Med 5:2. https:\/\/doi.org\/10.21037\/atm.2016.12.33","journal-title":"Ann Transl Med"},{"key":"2360_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/lctt.S269307","volume":"12","author":"T Fujino","year":"2021","unstructured":"Fujino T, Suda K, Mitsudomi T (2021) Lung cancer with MET exon 14 skipping mutation: genetic feature, current treatments, and future challenges. Lung Cancer (Auckl) 12:35\u201350. https:\/\/doi.org\/10.2147\/lctt.S269307","journal-title":"Lung Cancer (Auckl)"},{"key":"2360_CR34","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cell.2018.07.045","volume":"175","author":"W Minzel","year":"2018","unstructured":"Minzel W, Venkatachalam A, Fink A, Hung E, Brachya G, Burstain I, Shaham M, Rivlin A, Omer I, Zinger A et al (2018) Small molecules co-targeting CKI\u03b1 and the transcriptional kinases CDK7\/9 control AML in preclinical models. Cell 175:171\u201385e25. https:\/\/doi.org\/10.1016\/j.cell.2018.07.045","journal-title":"Cell"},{"key":"2360_CR35","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/2159-8290.Cd-24-0417","volume":"15","author":"CA Febres-Aldana","year":"2025","unstructured":"Febres-Aldana CA, Vojnic M, Odintsov I, Zhang T, Cheng R, Beach CZ, Lu D, Mattar MS, Gazzo AM, Gili L et al (2025) Pan-cancer analysis of oncogenic MET fusions reveals distinct pathogenomic subsets with differential sensitivity to MET-targeted therapy. Cancer Discov 15:1141\u20131158. https:\/\/doi.org\/10.1158\/2159-8290.Cd-24-0417","journal-title":"Cancer Discov"},{"key":"2360_CR36","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41571-025-01051-9","volume":"22","author":"JB Lee","year":"2025","unstructured":"Lee JB, Shim JS, Cho BC (2025) Evolving roles of MET as a therapeutic target in NSCLC and beyond. Nat Rev Clin Oncol 22:640\u2013666. https:\/\/doi.org\/10.1038\/s41571-025-01051-9","journal-title":"Nat Rev Clin Oncol"},{"key":"2360_CR37","doi-asserted-by":"publisher","first-page":"0019","DOI":"10.34133\/cancomm.0019","volume":"46","author":"Z Bao","year":"2026","unstructured":"Bao Z, Xue Y, Liu Y, Li S, Wang L, Qu Y, Mou Y, Yu R, Wu J, Yao Y et al (2026) Vebreltinib for previously treated astrocytoma, IDH-mutant, grade 4, and glioblastoma, IDH wild-type with PTPRZ1-MET fusion gene: a multicenter, phase III randomized, open-label trial. Cancer Commun (Lond) 46:0019. https:\/\/doi.org\/10.34133\/cancomm.0019","journal-title":"Cancer Commun (Lond)"},{"key":"2360_CR38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/s1470-2045(25)00594-7","volume":"27","author":"YL Wu","year":"2026","unstructured":"Wu YL, Yao Y, Yang JJ, Wu L, Zhang W, Wang Y, Xu HP, Song Y, Zhang Y, Zhao J et al (2026) Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study. Lancet Oncol 27:36\u201344. https:\/\/doi.org\/10.1016\/s1470-2045(25)00594-7","journal-title":"Lancet Oncol"},{"key":"2360_CR39","doi-asserted-by":"publisher","unstructured":"Conciatori F, Ciuffreda L, Bazzichetto C, Falcone I, Pilotto S, Bria E, Cognetti F, Milella M (2018) mTOR cross-talk in cancer and potential for combination therapy. Cancers (Basel) 10. https:\/\/doi.org\/10.3390\/cancers10010023","DOI":"10.3390\/cancers10010023"},{"key":"2360_CR40","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-023-36881-7","volume":"14","author":"HJ Liu","year":"2023","unstructured":"Liu HJ, Du H, Khabibullin D, Zarei M, Wei K, Freeman GJ, Kwiatkowski DJ, Henske EP (2023) mTORC1 upregulates B7-H3\/CD276 to inhibit antitumor T cells and drive tumor immune evasion. Nat Commun 14:1214. https:\/\/doi.org\/10.1038\/s41467-023-36881-7","journal-title":"Nat Commun"},{"key":"2360_CR41","doi-asserted-by":"publisher","unstructured":"Cao L, Xu Y, Hu Y, Huang X, Fu F, Zhan S, Huang L, Feng Y, Irene Y, Li H et al (2025) Identification of c-Met on tumor cells as a novel receptor for B7-H3 entails implications for cancer cell stemness and targeted therapy. MedComm (2020) 6:e70332. https:\/\/doi.org\/10.1002\/mco2.70332","DOI":"10.1002\/mco2.70332"},{"key":"2360_CR42","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1186\/s40001-025-02729-7","volume":"30","author":"W He","year":"2025","unstructured":"He W, Li H, Sun W, Zhang Y, Wu D, Ao C, Wang J, Yang Y, Xiao X, Zhang L et al (2025) B7-H3 and c-MET in advanced prostate cancer: exploring possibilities of novel bi-specific drug development. Eur J Med Res 30:467. https:\/\/doi.org\/10.1186\/s40001-025-02729-7","journal-title":"Eur J Med Res"},{"key":"2360_CR43","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.3389\/fimmu.2020.02135","volume":"11","author":"N Nishikoba","year":"2020","unstructured":"Nishikoba N, Kumagai K, Kanmura S, Nakamura Y, Ono M, Eguchi H, Kamibayashiyama T, Oda K, Mawatari S, Tanoue S et al (2020) HGF-MET signaling shifts M1 macrophages toward an M2-like phenotype through PI3K-mediated induction of arginase-1 expression. Front Immunol 11:2135. https:\/\/doi.org\/10.3389\/fimmu.2020.02135","journal-title":"Front Immunol"},{"key":"2360_CR44","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3892\/or.2019.7206","volume":"42","author":"L Chen","year":"2019","unstructured":"Chen L, Shi Y, Zhu X, Guo W, Zhang M, Che Y, Tang L, Yang X, You Q, Liu Z (2019) IL\u201310 secreted by cancer\u2013associated macrophages regulates proliferation and invasion in gastric cancer cells via c\u2013Met\/STAT3 signaling. Oncol Rep 42:595\u2013604. https:\/\/doi.org\/10.3892\/or.2019.7206","journal-title":"Oncol Rep"},{"key":"2360_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Liu L, Liu J, Dang P, Hu S, Yuan W, Sun Z, Liu Y, Wang C (2023) Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer 22:58. https:\/\/doi.org\/10.1186\/s12943-023-01725-x","journal-title":"Mol Cancer"},{"key":"2360_CR46","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V et al (2013) CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19:1264\u20131272. https:\/\/doi.org\/10.1038\/nm.3337","journal-title":"Nat Med"},{"key":"2360_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-025-01727-z.Song","author":"WQ Song","year":"2026","unstructured":"Song WQ, Wu YQ, Zhu QF, Xia XP, Wang R, Yang L, Hu LH, Wang JW, Huang YZ, Wang HY (2026) CSF1R inhibitor C19 for glioma immunotherapy enabled by brain-targeting liposomal delivery. Acta Pharmacol. https:\/\/doi.org\/10.1038\/s41401-025-01727-z.Song","journal-title":"Acta Pharmacol"},{"key":"2360_CR48","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.1158\/1078-0432.Ccr-08-0652","volume":"14","author":"DD Hu-Lowe","year":"2008","unstructured":"Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY et al (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272\u20137283. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-08-0652","journal-title":"Clin Cancer Res"},{"key":"2360_CR49","doi-asserted-by":"publisher","first-page":"118762","DOI":"10.1016\/j.ijpharm.2019.118762","volume":"572","author":"T Takenaka","year":"2019","unstructured":"Takenaka T, Nakai S, Katayama M, Hirano M, Ueno N, Noguchi K, Takatani-Nakase T, Fujii I, Kobayashi SS, Nakase I (2019) Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells. Int J Pharm 572:118762. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118762","journal-title":"Int J Pharm"},{"key":"2360_CR50","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/0008-5472.Can-09-1751","volume":"70","author":"CM Chresta","year":"2010","unstructured":"Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P et al (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70:288\u2013298. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-1751","journal-title":"Cancer Res"},{"key":"2360_CR51","doi-asserted-by":"publisher","first-page":"E11138","DOI":"10.1073\/pnas.1801156115","volume":"115","author":"NS Banerjee","year":"2018","unstructured":"Banerjee NS, Moore DW, Broker TR, Chow LT (2018) Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification. Proc Natl Acad Sci U S A 115:E11138\u2013e47. https:\/\/doi.org\/10.1073\/pnas.1801156115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2360_CR52","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1158\/1535-7163.Mct-11-0693","volume":"11","author":"M Wong","year":"2012","unstructured":"Wong M, Tan N, Zha J, Peale FV, Yue P, Fairbrother WJ, Belmont LD (2012) Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models. Mol Cancer Ther 11:1026\u20131035. https:\/\/doi.org\/10.1158\/1535-7163.Mct-11-0693","journal-title":"Mol Cancer Ther"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-026-02360-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02360-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02360-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:27:27Z","timestamp":1789954047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40478-026-02360-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2360"],"URL":"https:\/\/doi.org\/10.1186\/s40478-026-02360-5","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"11 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of Beijing Tiantan Hospital, Capital Medical University (KYSQ2025-456-01). Written informed consent was obtained from all patients enrolled in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"191"}}